Adjustment of blood coagulation for cardiopulmonary bypass surgery: Optimal dosage of tranexamic acid using thromboelastometry
Not Applicable
Completed
- Conditions
- patients undergoig cardiac surgery with cardiopulmonary bypass
- Registration Number
- JPRN-UMIN000009883
- Lead Sponsor
- agasaki univesity Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
Not provided
Exclusion Criteria
renal dysfunction
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does tranexamic acid target in cardiopulmonary bypass-induced coagulopathy?
How does thromboelastometry-guided tranexamic acid dosing compare to standard antifibrinolytic protocols in cardiac surgery?
Which coagulation biomarkers are most predictive of optimal tranexamic acid response during cardiopulmonary bypass?
What are the potential adverse events associated with thromboelastometry-adjusted tranexamic acid regimens in cardiac surgery?
Are there alternative antifibrinolytic agents or combination therapies that show superior efficacy to tranexamic acid in cardiopulmonary bypass procedures?